Double-stranded RNA molecules targeted to gene promoter regions can induce transcriptional gene silencing in a DNA cytosine methylation-dependent manner in plants (RNAdependent DNA methylation) [1] [2] [3] . Whether a similar mechanism exists in mammalian systems is a vital and controversial issue [4] [5] [6] . DNA methylation is an important component in mammalian gene silencing for normal processes such as gene imprinting and X-chromosome inactivation 7-9 , and aberrant CpG island hypermethylation at tumor-suppressor promoters is associated with transcriptional silencing and loss of gene function in cancer 10 . Hence, we investigated whether RNAdependent DNA methylation might operate in human cancers to mediate epigenetic silencing using the endogenous gene CDH1 as a potential target. The loss of this cell-cell adhesion factor facilitates the metastatic process, and its promoter is frequently hypermethylated in breast and other cancers [11] [12] [13] .
Double-stranded RNA molecules targeted to gene promoter regions can induce transcriptional gene silencing in a DNA cytosine methylation-dependent manner in plants (RNAdependent DNA methylation) [1] [2] [3] . Whether a similar mechanism exists in mammalian systems is a vital and controversial issue [4] [5] [6] . DNA methylation is an important component in mammalian gene silencing for normal processes such as gene imprinting and X-chromosome inactivation [7] [8] [9] , and aberrant CpG island hypermethylation at tumor-suppressor promoters is associated with transcriptional silencing and loss of gene function in cancer 10 . Hence, we investigated whether RNAdependent DNA methylation might operate in human cancers to mediate epigenetic silencing using the endogenous gene CDH1 as a potential target. The loss of this cell-cell adhesion factor facilitates the metastatic process, and its promoter is frequently hypermethylated in breast and other cancers [11] [12] [13] .
We found that, although small double-stranded RNAs targeted exclusively to the CDH1 promoter could effectively induce transcriptional repression with chromatin changes characteristic of inactive promoters, this was entirely independent of DNA methylation. Moreover, we could accomplish such silencing in a cancer cell line genetically modified to lack virtually any capacity to methylate DNA.
To test whether double-stranded RNAs (dsRNAs) could induce transcriptional gene silencing at the endogenous CDH1 promoter, we transfected HCT116 human colorectal cancer cells with two 21-nucleotide-long dsRNA oligonucleotides (dsCDH1-1 and dsCDH1-2). These sequences are homologous to the CpG island of the CDH1 promoter but do not overlap any known transcribed sequences ( Fig. 1a and Supplementary Note online). When both oligonucleotides were administered simultaneously, CDH1 protein levels decreased to be barely detectable by day 7 of treatment, compared with mock treatment or treatment with dsCtrl, a scrambled control dsRNA oligonucleotide (Fig. 1b) . We verified this decrease in CDH1 expression by realtime RT-PCR (qRT-PCR) and found a corresponding decline in CDH1 mRNA level in cells treated with dsCDH1s compared with untreated cells (Fig. 1c) . When used alone, dsCDH1-1 resulted in a greater downregulation of CDH1 expression than dsCDH1-2 alone but a lesser downregulation than the two oligonucleotides combined (Fig. 1d) .
To establish that loss of the CDH1 protein was due to transcriptional silencing, we carried out nuclear run-on assays. CDH1 transcription on day 7 was 61% lower in cells treated with dsCDH1s, as detected by a 3¢ cDNA probe, than in cells treated with dsCtrl ( Fig. 1e) . Thus, promoter-targeting dsRNAs could effectively silence CDH1 transcription, resulting in a net decrease in protein production. Next, we examined the methylation status of the two regions targeted by dsCDH1s in the CDH1 CpG island, which is closely correlated to the silencing of this promoter 11, 12 . We analyzed the two target regions by methylation-specific PCR (MSP) to verify the presence of DNA methylation parallel to gene silencing 14 . MSP distinguishes between unmethylated and methylated alleles by using two sets of primers that amplify either unmethylated or methylated sequences after bisulfite treatment, which specifically converts unmethylated cytosines to uracils. In wild-type as well as control cells, the CDH1 promoter was fully unmethylated, resulting in a single band in the MSP analysis corresponding to the unmethylated allele (Fig. 2a) . To maximize the probability of observing a change in DNAmethylation patterns, we compared cells treated with both dsCDH1 oligonucleotides for 7 days (which produced the greatest silencing effect) with control cells. The MSP pattern of only unmethylated alleles was preserved in the cells treated with both dsCDH1s, indicative of an absence of DNA methylation at either of the two targeted CpG island sites.
Because MSP analysis examined only the few CpG sites in the sequences recognized by the primers, we carried out bisulfite sequencing to verify the methylation status of all 36 CpG sites in the target region. We used unbiased primers that do not contain CpG dinucleotides to amplify the bisulfite-converted promoter region and cloned and sequenced the resulting PCR products individually (Fig. 2b) . Cells treated with both dsCDH1s showed the same sporadic methylation at only a few CpG sites as did the control cells. These observations verified that although transcriptional silencing was induced by treatment with dsCDH1s, there was no change in DNA methylation. To confirm that our results were not unique to HCT116 cells, we tested the same breast cancer cells, MCF-7, used in a silencing strategy virtually identical to ours for CDH1 and found to produce transcriptional silencing with simultaneous DNA methylation 4 . Western-blot analysis showed that CDH1 protein level was reduced by 60% in cells treated with both dsCDH1s for 7 days compared with mock-treated MCF-7 cells or MCF-7 cells treated with dsCtrl (Fig. 3a) . CDH1 expression, as assayed by qRT-PCR, was reduced by 50% in MCF-7 cells treated with dsCDH1s relative to controls (Fig. 3b) . But we observed no DNA methylation by MSP analysis (Fig. 3c) or by bisulfite sequencing (Fig. 3d) . Thus, in both breast and colon cancer cells, we observed CDH1 gene silencing in the absence of DNA methylation, confirming that the dsRNA-dependant transcriptional silencing (RdTS) pathway is active in more than one human cancer cell type.
In Arabidopsis thaliana, the RNA-dependent DNA methylation (RdDM) pathway also involves chromatin modifications [15] [16] [17] [18] . Moreover, emerging evidence shows that chromatin modifications, including histone methylation at key residues, have an important role in modulating gene expression in mammalian systems [19] [20] [21] [22] . Therefore, we explored the possibility that RdTS may result in histone modification changes in the CDH1 promoter in HCT116 cells. Chromatin immunoprecipitation (ChIP) assays on the CDH1 promoter, using two sets of PCR primers spanning the CDH1 core promoter, showed the expected presence of dimethylation at Lys4 of histone H3 (H3K4me2), a histone mark generally associated with actively transcribed promoters, in all treatment groups (Fig. 2c) . But dimethylation at Lys9 of histone H3 (H3K9me2), a modification present at inactive promoters, was detected only at the CDH1 promoter in cells treated with dsCDH1-1 (Fig. 2d) . We also carried out PCR on the same set of immunoprecipitated DNA fractions for GAPDH and MLH1 promoters as controls. The relative histone modification enrichments at these nontargeted promoters were similar in all samples (Supplementary Relative quantity Relative quantity Fig. 1 online) . These data confirm that RdTS in human cancer cells also involves histone modifications corresponding to a conversion from an active to silent state, as previously reported 4, 5 .
Because we observed effective RdTS without any DNA methylation changes, we tested whether RdTS could be induced in the absence of the DNA methylation machinery. DNA methylation in humans is catalyzed by three known functional enzymes, DNA methyltransferases (DNMTs) 1, 3a and 3b. DNMT1 and DNMT3b cooperate in HCT116 cells to maintain DNA methylation and account for almost all DNMT activities in these cells 23 (Fig. 4a ). The decrease in protein level was well correlated to a decrease in CDH1 mRNA level, as verified by qRT-PCR (Fig. 4b) . MSP analysis of the target promoter indicated a lack of DNA methylation, even though a strong silencing effect was apparent (Fig. 4c) . Bisulfite sequencing of the CDH1 promoter in these cells also confirmed the absence of DNA methylation (Fig. 4d) . This silencing in the absence of the major DNMTs supports the notion that acute RdTS in human colon cancer cells does not require DNA methylation.
We observed promoter silencing by dsRNAs in the absence of DNA methylation, whereas others observed both events for the same gene in some of the same human cancer cell types 4 . RdDM has also been reported for the EF1a promoter in human fibroblasts 5 . What accounts for these opposing results? We believe the answer may lie in the types of DNA methylation assays done and how they were done. First, the DNA methylation observed previously 4 included CpNpG methylation as a consequence of dsRNA targeting to the CDH1 promoter in MCF-7 cells. In plants, RdDM induces DNA methylation in the context of CpNpG and CpG in the targeted promoter 2 . Although CpNpG and CpG methylation both have strong correlations to gene silencing in plants, CpNpG methylation is rare and has no documented functional implications for gene silencing in humans. We found no CpNpG methylation in our bisulfite-sequenced region, which overlaps the region examined previously 4 . Unconverted cytosines in non-CpG contexts are often indicative of incomplete bisulfite conversions, allowing unmethylated cytosine residues in both CpG and non-CpG contexts to remain as cytosines. Such nonconversions may explain part of the differences in the bisulfite sequencing results between our study and the previous study 4 . Furthermore, the PCR primers used previously 4 to obtain the initial bisulfite sequencing template contain CpG sites that may bias the amplification step and produce problematic bisulfite sequencing results that are difficult to interpret 4 . A third problem in the sequencing data for CDH1 concerns the methylation status for two Alu repeats upstream of the 5¢ CpG island in the CDH1 promoter region. These sequences were found to be completely unmethylated 4 , whereas previous characterization of this region in MCF-7 cells showed, as is true for most Alu repeats, dense methylation even though the adjacent CDH1 proximal promoter region is unmethylated 12 . Finally, in the work with the silencing of the EF1a promoter in human fibroblasts, the DNA methylation data remain to be verified because the DNA methylation analyses were not as extensive and the indirect evidence for 5¢-aza-deoxycytidine and trichostatin A coadministration alleviating the silencing was difficult to interpret. Trichostatin A is a histone-deacetylase inhibitor, and 5¢-aza-deoxycytidine, though a DNMT inhibitor, can reactivate promoters that contain little or no DNA methylation 24 .
Taken together, our data strongly suggest that dsRNA species can induce effective transcriptional gene silencing in human colon and breast cancer cell lines and that this silencing does not involve DNA methylation changes in the acute time frame in which our experiments were done. This phenomenon is different from the description of RdDM in plants: namely, the silencing effect is not accompanied by DNA methylation changes. Our observations are also consistent with data from Schizosaccharomyces pombe, in which silencing effects and heterochromatin formation induced by dsRNAs were achieved in the absence of DNA methylation [25] [26] [27] . Also, multiple oligonucleotides 
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simultaneously targeting the same promoter have a synergistic silencing effect on the targeted promoter both in our hands and in other studies. This may be analogous to the plant system, in which RdDM triggers are usually long dsRNA molecules that span a few hundred base pairs of the target promoter and are later processed to smaller species of 21-30 bp (ref. 15) . DNA methylation may still be involved in a prolonged silencing event in human cells; in A. thaliana, RdDM is studied in the progenies of plants that received the initial dsRNA trigger and requires intact DNMTs to propagate the silencing 15, 28, 29 . Therefore, future experiments in mammalian systems should include a thorough examination of the long-term outcomes of RdTS. Most notably, the presence of RdTS indicates that this might be an existing gene regulatory mechanism in humans, even though we are currently unable to verify that it initiates tumor-suppressor gene hypermethylation in human cancers.
METHODS
Transfection and cell culture. We obtained HCT116 and MCF-7 cells from American Type Culture Collection and cultured them as directed. We derived DKO cells from HCT116 cells and maintained them in the same manner 23 . We obtained the dsRNA oligonucleotides from Dharmacon with the UU overhang option (sequences listed in Supplementary Table 1 online) . We transfected cells with 60 nM dsRNA using Lipofectamine 2000 (Invitrogen) at 24-h intervals and replaced the transfection medium with normal complete medium after 4 h.
Western blotting. We analyzed 10 mg of cell lysates by western blotting using mouse antibodies to CDH1 (1:2,500 dilution, BD 610181) and to b-actin (1:10,000 dilution, Sigma A5441). We quantified the resulting blots by densitometry analysis using Scion Image software.
qRT-PCR. We extracted total RNA from the treated cells with RNeasy Mini Kit (Qiagen 74104) and treated them with DNase (Qiagen 79254). We carried out qRT-PCR analyses using iScript Onestep RT-PCR Kit with SYBR Green (Bio-Rad 170-8892). Primers used for CDH1 and GAPDH qRT-PCR are listed in Supplementary Table 1 online. We carried out PCR reactions at a melting temperature of 55 1C. Data are presented as relative CDH1 expression, calculated as follows: (starting quantity of CDH1/starting quantity of GAPDH) sample /(starting quantity of CDH1/starting quantity of GAPDH) mock .
Nuclear run-on assay. We carried out the nuclear run-on assays in accordance with the Current Protocol of Molecular Biology. We used 10 6 nuclei per sample in the reaction with a 32 p-UTP (NEN BLU507X500UC). We hybridized the purified transcripts to a nylon membrane (PerkinElmer NEF976) containing immobilized nucleic acids corresponding to the 3¢ (+3301 to +4517) region of the CDH1 cDNA and to the GAPDH cDNA (+28 to +479).
DNA methylation analysis. We extracted genomic DNA and treated it with sodium bisulfite as previously described 30 . We carried out MSP on the CDH1 promoter with two sets of previously described primers spanning the CpG island (I2 and I3) of this region (Supplementary Table 1 online) 12 . Bisulfite sequencing primers are listed in Supplementary Table 1 online. We then cloned the PCR products into the TOPO TA vector (Invitrogen K2000-01SC) and sequenced them with the M13R primer.
ChIP assay and real-time PCR. We cross-linked cells and processed them in accordance with the UpState Chromatin Immunoprecipitation (ChIP) Assay Kit protocol (UpState 17-295). We used 2 Â 10 6 cells for each immunoprecipitation reaction. We used rabbit antibody to H3K4me2 (5 mg per immunoprecipitation, Upstate 07-030) and rabbit antibody to H3K9me2 (10 mg per immunoprecipitation, a gift from T. Jenuwein, Research Institute of Molecular Pathology, The Vienna Biocenter, Vienna, Austria) for specific immunoprecipitation of the respective histone residues and used rabbit antibody to hemagglutinin (10 mg per immunoprecipitation, Santa Cruz SC805) as the control. We used 50 ml of sonicated, preimmunoprecipitated DNA from each sample as input controls. We analyzed the ChIP results by real-time PCR using the QuantiTect SYBR Green PCR Kit (QIAGEN 204143) with two sets of CDH1 promoter specific primers spanning the CpG island of interest (Supplementary Table 1 online). We used a set of serially diluted DNA standards to calculate the starting quantities in each PCR reaction. We normalized the final results for each sample to the inputs. We also carried out PCR of GAPDH and MLH1 on the same sets of immunoprecipitated DNA fractions as controls.
Note: Supplementary information is available on the Nature Genetics website. 
